NetworkNewsBreaks – Immunic, Inc. (NASDAQ: IMUX) Secures $15M in Registered Direct Offering
Immunic (NASDAQ: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, has closed a sale of 1,764,706 shares of common stock with certain institutional investors, led by Altium Capital. According to the update, Immunic secured approximately $15 million in gross proceeds, with each of the shares sold at a price of $8.50. Immunic intends to use the proceeds to fund the ongoing clinical development of its three small molecule products: IMU-838, IMU-935 and IMU-856, as well as for other general corporate purposes, including to investigate its lead asset, IMU-838,…







